GENFIT S.A PE Ratio 2019-2022 | GNFT

Current and historical p/e ratio for GENFIT S.A (GNFT) from 2019 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. GENFIT S.A PE ratio as of January 27, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

GENFIT S.A PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-27 4.36 inf
2022-06-30 3.22 0 0.00
2021-06-30 3.80 0 0.00
2020-12-31 4.80 0 0.00
2020-06-30 5.51 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.208B $0.101B
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00